新诊断前列腺癌胚系检测的临床意义
本文为非系统性综述,梳理专业学会与共识会议关于前列腺癌胚系检测的指南推荐及其管理影响,并回顾临床实践中检测应用现状。指南普遍推荐转移性前列腺癌行胚系检测,尤其BRCA2检测;局限性病变则依据组织学特征与家族史选择检测,但各指南标准不一。实践中胚系检测应用存在不足,需优化策略。
要点
- 转移性前列腺癌推荐胚系检测,BRCA2检测获强证据支持。
- 局限性前列腺癌依据组织学特征和家族史选择检测,标准各指南不一。
- 胚系检测 uptake 在部分实践场景不足,需优化策略。
核心结论
- 胚系评估在转移性前列腺癌管理中日益重要,也可能影响局限性病变预后。
- 胚系突变对患者及其家族具有重要遗传性癌症意义。
- 部分实践场景中胚系评估应用不足,需优化策略。
研究设计与样本
- 非系统性综述,汇总专业学会与共识会议的前列腺癌胚系检测指南及支持证据。
- 补充文献回顾胚系检测与精准医学在实践中的应用情况。
主要发现
- 多个指南和共识小组推荐转移性前列腺癌男性行胚系检测。
- 指南支持转移性前列腺癌行BRCA2检测,因前列腺癌风险、侵袭性和PARP抑制剂候选资格证据强。
- 转移性疾病中其他DNA修复基因检测也获各指南支持。
- 部分指南将帕博利珠单抗免疫治疗列为DNA错配修复缺陷男性的选项。
- 局限性病变中,胚系检测基于组织学特征和家族史推荐,标准各指南不同。
关键数值与推荐
- 转移性前列腺癌:推荐胚系检测,BRCA2检测获强证据支持。
- 转移性前列腺癌:其他DNA修复基因检测获指南支持。
- DNA错配修复缺陷:部分指南将帕博利珠单抗列为选项。
- 局限性前列腺癌:基于组织学特征和家族史推荐胚系检测,标准各指南不一。
临床怎么用
- 转移性前列腺癌患者应评估胚系检测,尤其BRCA2及其他DNA修复基因。
- 局限性前列腺癌患者依据组织学特征和家族史决定是否行胚系检测。
- 胚系检测结果可指导治疗选择、癌症筛查及家族癌症风险评估。
- 需关注实践中的检测应用不足,采取策略优化胚系评估。
局限性
- 本文为非系统性综述,未采用系统检索方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Germline testing (GT) is increasingly impacting prostate cancer (PCa) management and screening, with direct effects in urology, medical oncology, and radiation oncology. The majority of testing indications and recommendations center on men with metastatic disease, although guidelines now encompass newly diagnosed, early-stage PCa and entail assessment of personal history, pathologic features, and family history to determine eligibility for testing. OBJECTIVE: To describe current guidelines on GT for men with PCa and the impact on management. An additional objective was to review the literature on current uptake of GT across practice settings. EVIDENCE ACQUISITION: A nonsystematic review was performed of current guidelines on GT in PCa from professional societies and consensus conferences, detailing supporting evidence for these recommendations. This was supplemented by a literature review of uptake of GT and precision medicine in practice. EVIDENCE SYNTHESIS: Multiple guidelines and consensus panels recommend GT for men with metastatic PCa. Guidelines endorse BRCA2 testing in metastatic PCa because of strong evidence for PCa risk, aggressiveness, and PARP inhibitor candidacy. Testing of additional DNA repair genes in metastatic disease is also endorsed across guidelines. Immunotherapy with pembrolizumab is an option in some guidelines for men with DNA mismatch repair deficiency. In localized disease, GT is recommended on the basis of histologic features and family history; criteria vary between guidelines. GT for localized disease informs hereditary cancer risk and will probably impact future PCa management. Practice gaps exist regarding utilization of GT. CONCLUSIONS: Germline evaluation is increasingly important in the management of men with metastatic PCa and may also affect the prognosis for men with localized disease. The presence of germline mutations has important hereditary cancer implications for men and their families. Uptake of germline evaluation may be underutilized in some practice settings, so strategies for optimization are required. PATIENT SUMMARY: Patients with prostate cancer should talk to their doctor about the pros and cons of genetic testing, with attention to family history and cancer features. Genetic testing can have important implications for treatment, cancer screening, and family cancer risk.
引用
- Loeb S, Giri VN. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2020. PMID: 33390340. doi:10.1016/j.euo.2020.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。